Background/Aims: Patients with osteogenesis imperfecta (OI) present with various degrees of short stature and nutritional disorders. Thus, we aimed to evaluate anthropometric and nutritional parameters in OI children and their variability among various types. Methods: Eighty-four patients with OI (types I, II, and IV) were subjected to the following anthropometric measurements: standing height (Ht), sitting height (SH), arm span, weight (Wt), and head circumference (HC), with calculation of Ht, SH, Wt, body mass index (BMI), and HC standard deviation scores (SDSs), and relative arm span. Triceps skinfold thickness (TSFT), subscapular skinfold thickness (SSFT), and mid upper arm circumference (MUAC) were measured, as well as dietary intake of macronutrients and calcium; also, energy requirements were calculated. Results: Ht SDS was reduced in OI-III and OI-IV compared to OI-I; SH SDS was reduced in OI-III compared to OI-I. HC SDS was more increased in OI-III than in OI-I and OI-IV. BMI SDS correlated with TSFT, SSFT, and MUAC. OI-III patients had the highest percentage of energy intake. The frequency of low macronutrient and calcium intake was highest in OI-III, while the frequency of low fat intake was highest in OI-I. Conclusions: Anthropometric and nutritional parameters differ among OI types. Assessment of anthropometric measurements and nutritional status in OI patients is important.

1.
Sillence DO, Senn A, Danks DM: Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101-116.
2.
Rauch F, Lalic L, Roughley P, Glorieux FH: Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 2010;25:1367-1374.
3.
Keupp K, Beleggia F, Kayserili H, Barnes AM, Steiner M, Semler O, Fischer B, Yigit G, Janda CY, Becker J, Breer S, Altunoglu U: Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 2013;92:565-574.
4.
Pyott SM, Tran TT, Leistritz DF, Pepn MG, Mendelsohn NJ, Temme RT, Fernandez BA, Elsayed SM, Elsobky E, Verma I, Nair S, Turner EH, Smith JD, Jarvik GP, Byers PH: WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet 2013;92:590-559.
5.
Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Korkko J, Prockop DJ, De Paepe A, Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish R, Byers PH: Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 2007;28:209-221.
6.
Venturi G, Tedeschi E, Mottes M, Valli M, Camilot M, Viglio S, Antoniazzi F, Tatò L: Osteogenesis imperfecta: clinical, biochemical and molecular findings. Clin Genet 2006;70:131-139.
7.
Becker J, Semler O, Gilissen C, Li Y, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K, de Vries P, Wirth B, Schoenau E, Wollnik B, Veltman J, Hoischen A, Netzer C: Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal recessive osteogenesis imperfecta. Am J Hum Genet 2011;88:362-371.
8.
Martínez-Glez V, Valencia M, Caparrós-Martín JA, Aglan M, Temtamy S, Tenorio J, Pulido V, Lindert U, Rohrbach M, Eyre D, Giunta C, Lapunzina P, Ruiz-Perez VL: Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat 2012;33:343-350.
9.
Farber CR, Reich A, Barnes AM, Becerra P, Rauch F, Cabral WA, Bae A, Quinlan A, Glorieux FH, Clemens TL, Marini JC: A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor. J Bone Miner Res 2014;29:1402-1411.
10.
Lund AM, Muller J, Skovby F: Anthropometry of patients with osteogenesis imperfecta. Arch Dis Child 1999;80:524-528.
11.
Van Dijk FS, Pals G, Van Rijn RR, Nikkels PGJ, Cobben JM: Classification of osteogenesis imperfecta revisited. Eur J Med Genet 2010;53:1-5.
12.
Castillo H, Samson-Fang L: Effect of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 2009;5:17-29.
13.
Chagas CA, Roque JP, Peters BSE, Lazaretti-Castro M, Martini LA: Do patients with osteogenesis imperfecta need individualized nutritional support? Nutrition 2012;28:138-142.
14.
Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux F: Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006;148:456-460.
15.
Crawford PB, Obarzanek E, Morrison J, Sabry ZI: Comparative advantage of 3-day food records over 24-hour recall and 5-day food frequency validated by observation of 9- and 10-year-old girls. J Am Diet Assoc 1994;94:626-630.
16.
World Health Organization: Human Energy Requirements. Report of a Joint FAO/WHO/UNU Expert Consultation. Rome, Food and Agriculture Organization, 2001. http://www.fao.org/docrep/007/y5686e/y5686e00.htm.
17.
Heald FP, Gong EL: Diet, nutrition and adolescence; in Shills ME, Olson JA, Shike M, Ross AC (eds): Modern Nutrition in Health and Disease. Philadelphia, Lippincott Williams & Wilkins, 2006, pp 857-867.
18.
World Health Organization: Diet, Nutrition and the Prevention of Chronic Diseases. WHO Technical Report Series 916. Geneva, World Health Organization, 2003. http://whqlibdoc.who.int/trs/who_trs_916.pdf.
19.
Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board: Dietary Reference Intakes for Calcium and Vitamin D. Washington, National Academy Press, 2010. http://www.nap.edu/openbook.php?record_id=13050&page=R1.
20.
World Health Organization: Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. Technical Report Series No. 854. Geneva, World Health Organization, 1995.
21.
Tanner JM, Whitehouse RH, Takaishi M: Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch Dis Child 1966;41:454-613.
22.
Hiernaux J, Tanner JM: Growth and physical studies; in Weiner JS, Lourie SA (eds): Human Biology: A Guide to Field Methods. London, Blackwell Scientific Publications, 1969.
23.
Cole TJ: A chart to link child centiles of body mass index, weight and height. Eur J Clin Nutr 2002;56:1194-1199.
24.
Lee RD, Nieman DC: Nutritional Assessment, ed 3. Boston, WCB/McGraw-Hill, 2003.
25.
Frisancho AR: Anthropometric Standards for the Assessment of Growth and Nutritional Status. Ann Arbor, University of Michigan Press, 1990.
26.
Zambrano MB, Brizola ES, Refosco L, Giugliani R, Félix TM: Anthropometry, nutritional status, and dietary intake in pediatric patients with osteogenesis imperfecta. J Am Coll Nutr 2014;33:18-25.
27.
Zeitlin L, Rauch F, Plotkin H, Glorieux FH: Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111:1030-1036.
28.
Aglan MS, Zaki ME, Hosny L, El-Houssini R, Oteify G, Temtamy SA: Anthropometric measurements in Egyptian patients with osteogenesis imperfecta. Am J Med Genet 2012;158:2714-2718.
29.
Hasegawa K, Inoue M, Seino Y, Morishima T, Tanaka H: Growth of infants with osteogenesis imperfecta treated with bisphosphonate. Pediatr Int 2009;51:54-58.
30.
Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP: Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 1993;45:261-264.
31.
Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, Rosenfeld R, Chrousos GP: The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 1993;76:251-256.
32.
Rauche F, Lalic L, Roughley P, Glorieux FH: Genotype-phenotype correlations in nonlethal osteogenesis imperfect caused by mutations in the helical domain of collagen type I. Eur J Hum Genet 2010;18:642-647.
33.
Ben Amor M, Francis H, Glorieux FH, Rauch F: Genotype-phenotype correlations in autosomal dominant osteogenesis imperfecta. J Osteoporos 2011;2011:540178.
34.
Rauche F, Lalic L, Roughley P, Glorieux FH: Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 2010;25:1367-1374.
35.
Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti D, Zamboni G, Tatò L: GH in combination with bisphosphonate treatment in osteogenesis imperfect. Eur J Endocrinol 2010;163:479-487.
36.
Montpetit K, Dahan-Oliel N, Ruck-Gibisa J, Fassier F, Rauch F, Glorieux F: Activities and participation in young adults with osteogenesis imperfecta. J Pediatr Rehabil Med 2011;4:13-22.
37.
Engelbert RH, Gulmans VA, Uiterwaal CS, Helders PJ: Osteogenesis imperfecta in childhood: perceived competence in relation to impairment and disability. Arch Phys Med Rehabil 2001;82:943-948.
38.
Cheung MS, Glourieux FH: Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord 2008;9:253-260.
39.
Glorieux FX: Osteogenesis imperfecta. Best Pract Res Clin Rheumatol 2008;22:85-100.
40.
Basel D, Steiner RD: Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med 2009;11:375-385.
41.
Fano V, Celin MR, del Pinto M, Buceta S, Obregón MG, Primomo C, García H, Miscione H, Lejarraga H: Osteogenesis imperfecta. Clinical, functional and multidisciplinary evaluation of 65 patients (in Spanish). An Pediatr 2010;72:324-330.
42.
Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ: Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehabil 2004;85:772-778.
43.
Sigulem DM, Devincenzi MU, Lessa AC: Diagnosis of child and adolescent nutritional status. J Pediatr (Rio J) 2000;76:275-284.
44.
Addo OY, Himes JH: Reference curves for triceps and subscapular skinfold thicknesses in US children and adolescents. Am J Clin Nutr 2010;91:635-642.
45.
Jehn ML, Gittelsohn J, Treuth MS, Caballero B: Prevalence of overweight among Baltimore City schoolchildren and its associations with nutrition and physical activity. Obesity 2006;14:989-993.
46.
Ricardo GD, Caldeira GV, Corso ACT: Prevalence of overweight and obesity and central adiposity indexes among school-aged children in Santa Catarina, Brazil. Rev Bras Epidemiol 2009;12:424-435.
47.
Zambon MP, Zanolli ML, Marmo DB, Magna LA, Guimarey LM, Morcillo AM: Body mass index and triceps skinfold correlation in children from Paulínia city, São Paulo, SP. Rev Assoc Med Bras 2003;49:137-140.
48.
Cropp GJ, Myers DN: Physiological evidence of hypermetabolism in osteogenesis imperfecta. Pediatrics 1972;49:375-391.
49.
Pierry C, Mosca LN, Schena C, Santos LC: Dietary intake, calcium intake and anthropometry of adolescents of public and private school of Santos, SP. Pediatria 2010;32:197-203.
50.
Lerner BR, Lei DLM, Chaves SP, Freire RD: Consumption of calcium by adolescents from public schools in Osasco, São Paulo, Brazil. Rev Nutr 2000;13:57-63.
51.
Castro TG, Novaes JF, Silva MR, Costa NMB, Franceschini SCC, Tinoco ALA, Leal PFG: Characteristics of dietary intake, socioeconomic environment and nutritional status of preschoolers at public kindergartens. Rev Nutr 2005;18:321-330.
52.
Bueno AL, Czepielewski MA: The importance for growth of dietary intake of calcium and vitamin. J Pediatr (Rio J) 2008;84:386-394.
53.
Flynn A: The role of dietary calcium in bone health. Proc Nutr Soc 2003;62:851-858.
54.
Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC: Regulation of adiposity by dietary calcium. FASEB J 2000;14:1132-1138.
55.
Zemel MB: Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 2002;21:146-151.
56.
Kawai M, de Paula FJ, Rosen CJ: New insights into osteoporosis: the bone-fat connection. J Intern Med 2012;272:317-329.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.